IFF Announces Executive Leadership Team Aligned With New Operating Model
IFF (NYSE: IFF) announced changes to its executive leadership team, aligned with the Company’s external reporting structure.
After 21 years of dedicated service to IFF, Simon Herriott, president of Health and Biosciences, will step down. Effective March 1, Leticia Gonçalves, ADM’s president of precision fermentation and ADM Ventures, will join IFF as president of Health and Biosciences.
“Since 2019, Simon has driven growth and operational effectiveness through innovation, customer intimacy and supply chain development as president of our Health and Biosciences business unit,” said Erik Fyrwald, IFF CEO. “We’re grateful for Simon’s tremendous contributions to IFF and wish him well for the future. His dedication and leadership will leave a lasting impact on our organization.”
Gonçalves brings to IFF extensive experience with IFF’s end markets in innovation-based companies, having served in various senior global and regional P&L leadership roles at ADM, Bayer and Monsanto in Brazil, Europe and the United States. She was most recently president of precision fermentation and ventures at ADM, where she developed new businesses to serve growing customer needs across various food, health and wellness, agriculture and industrial applications. She also led ADM’s Specialty Ingredients and Foods businesses driving innovation, culture and productivity to maximize value creation across food security, supply chain resilience and sustainability. She is a board member of Emerson Electric.
“We’re excited to welcome Leticia to IFF,” said Fyrwald. “Her extensive experience driving P&L growth in innovation-led businesses and accelerating high-performing teams—coupled with her knowledge of our end markets—will be a great addition to our leadership team. I’m confident Leticia will continue to build on our cutting-edge biotechnology platform of probiotics, cultures and enzymes and drive our next phase of business growth.”
Also new to the executive leadership team, Andy Muller serves as IFF’s president of Food Ingredients. He joined IFF in December 2024 with a wealth of experience in food ingredients. Most recently, he served as president of Functional Ingredients and Solutions at Corbion where he focused on bakery, meat, dairy, confectionery, beverage industries, pet food and biochemicals. He spent 12 years with Danisco, later DuPont’s Nutrition and Health business, where he grew the business by expanding organizational capabilities, rationalizing the product portfolio, and refocusing efforts on core end-market applications. He serves on the board of PureField Ingredients.
“Andy’s deep experience in food ingredients and knowledge of our business will support our focus to deliver growth in our specialty ingredients business and increased value to our customers. We’re excited to have him on board as we continue to grow and innovate.”
Yuvraj Arora, previously President, Nourish, has assumed the role of President, Taste and Chief Commercial Officer. Ana Paula Mendonça, President, Scent, and Angela Strzelecki, President, Pharma Solutions, maintain their current divisional leadership roles.
IFF’s executive leadership team now includes:
- Erik Fyrwald, CEO
- Michael DeVeau, EVP, Chief Financial Officer
- Yuvraj Arora, President, Taste and Chief Commercial Officer
- Ana Paula Mendonça, President, Scent
- Leticia Gonçalves, President, Health & Biosciences
- Andy Muller, President, Food Ingredients
- Angela Strzelecki, President, Pharma Solutions
- Deborah Borg, EVP, Chief People & Culture Officer
- Ralph Finzel, EVP, Global Operations Officer
- Vic Verma, EVP, Chief Information Officer
- Jennifer Johnson, EVP, General Counsel and Corporate Secretary
- Steve Landsman, EVP, Business Development
Welcome to IFF
At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Learn more at iff.com, LinkedIn, Instagram and Facebook.
© 2025 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250220609936/en/
Contacts
Media Relations:
Paulina Heinkel
332.877.5339
Media.request@iff.com
Investor Relations:
Michael Bender
212.708.7263
Investor.Relations@iff.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AB InBev Reports First Quarter 2025 Results8.5.2025 08:03:00 EEST | Press release
Anheuser-Busch InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250507671244/en/ AB InBev Strategic Priorities Regulated information1 “Beer is a passion point for consumers. The strength of the beer category and the continued momentum of our megabrands delivered another quarter of profitable growth. EBITDA increased at the top-end of our outlook and the ongoing optimization of our business drove Underlying EPS growth of 7.1%. The consistent execution of our strategy by our teams and partners drove a solid start to the year and reinforces our confidence in delivering on our outlook for 2025.” – Michel Doukeris, CEO, AB InBev Revenue +1.5% Revenue increased by 1.5% with revenue per hl growth of 3.7%. Reported revenue decreased by 6.3% to 13 628 million USD, impacted by unfavorable currency translation. 4.4% increase in combined revenues of our megabrands, led by Corona, which g
Rimini Street and ServiceNow Partner with Apsen Farmacêutica to Deliver a Next-Generation Vision of Enterprise-Wide Workflow Automation7.5.2025 19:55:00 EEST | Press release
Knowledge 2025 —Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, management and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today at ServiceNow’s annual customer and partner event, Knowledge 2025, announced that Apsen Farmacêutica, a Brazilian pharmaceutical manufacturer, has partnered with Rimini Street and ServiceNow to implement a next-generation vision of enterprise-wide workflow automation. This new vision will enable autonomy across the company to help respond faster to market changes, reduce information silos and improve operational efficiency. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250507517040/en/ Rimini Street and ServiceNow Partner with Apsen Farmacêutica to Deliver a Next-Generation Vision of Enterprise-Wide Workflow Automation Apsen is prioritizing business needs above technology, leaning into a fl
Results from the VirTus Respiratory Research Ltd Human Rhinovirus Challenge Model Used to Advance Altesa BioSciences’ Lead Medicine into Advanced Clinical Trials7.5.2025 19:07:00 EEST | Press release
VirTus Respiratory Research Ltd, a leading respiratory-focused contract research organisation (CRO), today announced that results from their human rhinovirus challenge model in patients with chronic obstructive pulmonary disease (COPD) provided Altesa BioSciences with compelling evidence to advance their lead drug candidate, vapendavir, into large scale, late-stage clinical trials. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250507489716/en/ Professor Sebastian Johnston https://www.prnewswire.com/news-releases/altesa-biosciences-details-positive-topline-vapendavir-results-from-phase-2-placebo-controlled-rhinovirus-challenge-study-in-copd-patients-302448650.html Rhinovirus infection is the cause of at least half of the acute respiratory deteriorations experienced by the millions of patients with chronic obstructive lung disease. “Before advancing vapendavir into clinical trials testing vapendavir on thousands of patients c
FlightSafety International Announces Major Expansion at Farnborough Airport7.5.2025 18:56:00 EEST | Press release
FlightSafety International (FSI), a global leader in aviation training, is pleased to announce the expansion of its facilities at Farnborough Airport, the home of British aviation and Europe’s leading airport for premium air travel connectivity, highlighting its commitment to enhancing aviation safety and training excellence in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250506583636/en/ Rendering: arriving at FlightSafety International The new FSI centre is expected to open in the second quarter of 2027. Lease terms have been finalised and the planning application was submitted in January. Construction is scheduled to start in late 2025 and finish by early 2027. FSI has operated a training centre at Farnborough Airport since 2004. The new facilities will boost training capacity by 40-50%, enabling more aviation professionals access to FSI's world-class training programmes. The current facility is 4,680 square met
Verimatrix Positioned as a Leader and Ace Performer in the 2025 SPARK Matrix TM for In-App Protection by QKS Group7.5.2025 18:45:00 EEST | Press release
Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250507970501/en/ Verimatrix positioned as a Leader in the 2025 SPARK Matrix™ for In-App Protection by QKS Group. Verimatrix has been recognized for its comprehensive in-app protection capabilities, earning strong ratings across both Technology Excellence and Customer Impact in the latest SPARK Matrix™. The company has also been named an Ace Performer a recognition given to vendors that demonstrate revenue growth potential, partnership strategy, and customer acquisition—all evaluated over the last one-year period or since the previous SPARK Matrix assessment. The QKS Group SPARK Matrix™ provides competitive analysis & ranking of the leading In-App Protection vendors. For more information about Verimatrix, visit: https://www.verimatrix.com SPARK MatrixTM: In-App Protection, Q1 2025: https://qksgroup.com/market-research/spark-matrix-in-app-protection-q1-2025-8413 V
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom